(11)	SHARE-BASED COMPENSATION

The Company maintains a share-based compensation plan, the 2010 Employee, Director and Consultant Equity Incentive Plan, as amended (the “2010 Plan”), that has been approved by the Company’s shareholders. The 2010 Plan allows the Company, under the direction of the Compensation Committee of the Board of Directors, to make grants of stock options, restricted and unrestricted stock awards and other stock-based awards to employees, consultants and directors. On December 1, 2016, the shareholders approved an amendment to the 2010 Plan to add 2.5 to the number of shares of common stock available for grant. At September 30, 2017, 1.0 shares of common stock were available for issuance. If an option or RSU issued or awarded under the 2010 Plan is cancelled or expires without the issuance of shares of common stock, the unissued or reacquired shares, which were subject to the option or RSU, shall again be available for issuance pursuant to the 2010 Plan. In addition, as of September 30, 2017, the Company may grant up to 2.2 additional shares of common stock under the 2010 Plan if options previously granted under the Company’s terminated 2003 Employee, Director and Consultant Option Plan are cancelled or expire without the issuance of shares of common stock by the Company.

The number of shares, terms, and vesting periods are determined by the Company’s Board of Directors or a committee thereof on an option-by-option basis. Options generally vest ratably over service periods of four years. Options granted after December 5, 2012 expire eight years from the date of grant, and options granted prior to that date generally expire ten years from the date of grant. In September 2014, the Company began issuing restricted stock units (“RSUs”) in lieu of stock options. RSUs granted to employees generally vest ratably over four years on the anniversary date of the last day of the month in which the RSUs are granted. The number of RSUs awarded to certain executive officers may be reduced if certain additional performance metrics are not met. Options and restricted stock units granted to our non-employee directors vest in full upon completion of one year of service on the Board following the date of the grant.

Stock Options

A summary of the stock option activity under the Company’s plans for the three months ended September 30, 2017 is as follows:

	Number of shares			Weighted average exercise price
Options outstanding at June 30, 2017		8.0		$	24.67
Options granted		—		$	—
Less:
Options exercised		(0.4	)	$	22.75
Options canceled or expired		(0.1	)	$	26.56
Options outstanding at September 30, 2017		7.5		$	24.77
Options exercisable at September 30, 2017		7.5		$	24.77

As of September 30, 2017, there was no unrecognized share-based compensation expense related to stock options.

Restricted Stock Units

A summary of the RSU activity under the Company’s plans for the three months ended September 30, 2017 is as follows:

	Number of shares			Weighted average grant date fair value
RSUs outstanding at June 30, 2017		2.0		$	33.02
RSUs granted		1.0		$	32.56
Less:
RSUs vested		(0.5	)	$	35.16
RSUs canceled		(0.1	)	$	25.93
RSUs outstanding at September 30, 2017		2.4		$	32.84

As of September 30, 2017, there was $51.3 of total unrecognized share-based compensation expense related to RSUs that will be recognized over a weighted-average period of 2.6 years. This unrecognized compensation expense is equal to the fair value of RSUs expected to vest.

Employee Stock Purchase Plan

The Company also has an Employee Stock Purchase Plan that was approved by shareholders in 2012 (the “2012 Purchase Plan”), under which 2.0 shares of common stock have been authorized. Shares are issued under the 2012 Purchase Plan twice yearly at the end of each offering period. As of September 30, 2017, approximately 0.7 shares of common stock have been issued under the 2012 Purchase Plan.

Share-Based Compensation Expense

Share-based compensation expense recognized and included in the condensed consolidated statements of income and comprehensive income was allocated as follows:

	Three months ended
	September 30,
	2017		2016
Cost of molecular diagnostic testing	$	0.2	$	0.2
Cost of pharmaceutical and clinical services		0.1		0.1
Research and development expense		0.8		1.6
Selling, general, and administrative expense		5.3		5.9
Total share-based compensation expense	$	6.4	$	7.8